Vir Biotechnology, Inc. (VIR) and Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that they have selected a development candidate (DC) for VIR-2703 (ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 (COVID-19) genome.

Glaxo said it would invest more than £200m in the US company and that they would initially focus on speeding up development of Vir's antibody drugs, which could be used to treat Covid-19.